CinCor Pharma (CINC)

Company Profile

CinCor Pharma Inc. is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. The companys focus is on cardiovascular, metabolic and kidney diseases. CinCor Pharma was founded by Jon Isaacsohn, M.D., and Catherine Pearce, DHSc, MBA, in 2018.

Company profile

Ticker

CINC

Exchange

NASDAQ

Website

www.cincor.com/

CEO

Marc de Garidel

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001868734

Corporate docs

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

CINC stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$30.50

Low target

$30.00

High target

$31.00

Latest filings (excl ownership)

View all

15-12G

Securities registration termination

6 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

24 Feb 23

8-K

Completion of Acquisition or Disposition of Assets

Tender offer solicitation (amended)

24 Feb 23

SC TO-T/A

Third party tender offer statement (amended)

24 Feb 23

SC 14D9/A

Tender offer solicitation (amended)

23 Feb 23

SC TO-T/A

Third party tender offer statement (amended)

23 Feb 23

8-K

Regulation FD Disclosure

21 Feb 23

SC 14D9/A

Tender offer solicitation (amended)

15 Feb 23

Latest ownership filings

View all

Sofinnova Venture Partners X, L.P.

1 Mar 23

SC 13D/A

5AM Ventures VI, L.P.

GENERAL ATLANTIC, L.P.

Financial summary

Financial statements Chart CINC financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	292.56 mm	292.56 mm	292.56 mm	292.56 mm	292.56 mm	292.56 mm
Cash burn (monthly)	(no burn)	(no burn)	7.41 mm	6.88 mm	6.99 mm	7.08 mm
Cash used (since last report)	n/a	n/a	42.95 mm	39.84 mm	40.51 mm	41.03 mm
Cash remaining	n/a	n/a	249.60 mm	252.71 mm	252.05 mm	251.53 mm
Runway (months of cash)	n/a	n/a	33.7	36.7	36.0	35.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

CINC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	109	90	+21.1%
Opened positions	39	35	+11.4%
Closed positions	20	6	+233.3%
Increased positions	33	38	-13.2%
Reduced positions	19	12	+58.3%

13F shares	Current	Prev Q	Change
Total value	446.94 bn	1.51 bn	+29494.0%
Total shares	52.82 mm	52.28 mm	+1.0%
Total puts	561.20 k	76.70 k	+631.7%
Total calls	213.10 k	18.70 k	+1039.6%
Total put/call ratio	2.6	4.1	-35.8%

Largest owners	Shares	Value	Change
Sofinnova Investments	6.07 mm	$74.65 bn	-0.1%
Sofinnova Venture Partners X	6.07 mm	$208.40 mm	0.0%
5AM Venture Management	4.94 mm	$60.68 bn	0.0%
General Atlantic	4.21 mm	$51.73 bn	0.0%
5AM Ventures VI	3.84 mm	$61.96 mm	0.0%
CinRx Pharma	3.63 mm	$0.00	0.0%
Perceptive Advisors	2.58 mm	$31.66 bn	-22.1%
Adage Capital Partners GP, L.L.C.	1.99 mm	$24.51 bn	-34.2%
Orbimed Advisors	1.91 mm	$23.42 bn	+506.6%
venBio Global Strategic Fund III	1.86 mm	$30.04 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Orbimed Advisors	1.91 mm	+1.59 mm	+506.6%
venBio Partners	383.39 k	-1.48 mm	-79.4%
BVF	0.00	-1.31 mm	EXIT
Adage Capital Partners GP, L.L.C.	1.99 mm	-1.03 mm	-34.2%
Perceptive Advisors	2.58 mm	-730.32 k	-22.1%
Great Point Partners	1.02 mm	+717.83 k	+238.2%
BLK Blackrock	1.78 mm	+464.41 k	+35.2%
STT State Street	457.67 k	+457.67 k	NEW
Sphera Funds Management	529.64 k	+410.69 k	+345.3%
Silverarc Capital Management	395.38 k	+395.38 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CINC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Feb 23	Garidel Marc de	Common Stock	Sale back to company	Dispose D	No	No	0	200,000	0.00	0
24 Feb 23	Garidel Marc de	Common Stock		Dispose U	No	No	0	12,500	0.00	200,000
24 Feb 23	Garidel Marc de	Stock Option Common Stock	Sale back to company	Dispose D	No	No	7.62	601,901	4.59 mm	0
24 Feb 23	Garidel Marc de	Stock Option Common Stock	Sale back to company	Dispose D	No	No	5.82	726,483	4.23 mm	0
24 Feb 23	John F Thero	Stock Option Common Stock	Sale back to company	Dispose D	No	No	13.6	58,823	799.99 k	0
24 Feb 23	John F Thero	Stock Option Common Stock	Sale back to company	Dispose D	No	No	5.82	36,324	211.41 k	0
24 Feb 23	Catherine Pearce	Common Stock		Dispose U	Yes	No	0	1,500	0.00	0
24 Feb 23	Catherine Pearce	Common Stock	Sale back to company	Dispose D	No	No	0	15,000	0.00	0
24 Feb 23	Catherine Pearce	Common Stock		Dispose U	No	No	0	140,149	0.00	15,000
24 Feb 23	Catherine Pearce	RSU Common Stock	Sale back to company	Dispose D	No	No	0	13,236	0.00	0